Head-to-head comparison
| Property | Epithalon | FOXO4-DRI |
|---|---|---|
| Category | Longevity | Longevity |
| Legal Status | Research Only | Research Only |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~2-3 hours (estimated) | Unknown in humans; estimated hours based on peptide class |
| Mol. Weight | 390.35 Da | 4,826.5 Da |
| Side Effects | Injection site discomfort, Mild flu-like symptoms (rare), Drowsiness | Unknown in humans — no human safety data exists, Potential off-target apoptosis in non-senescent cells at high doses (animal studies), Injection site reactions |
Key differences
- Mechanism: Epithalon activates telomerase to add telomeric repeats (TTAGGG) to chromosome ends; FOXO4-DRI disrupts the FOXO4-p53 interaction to trigger selective apoptosis in senescent cells.
- Approach to aging: Epithalon aims to slow cellular aging by maintaining telomere length and restoring pineal gland function; FOXO4-DRI aims to remove already-aged senescent cells that drive chronic inflammation.
- Evidence base: Epithalon has 35+ years of research including a 15-year human observational study showing 1.6-1.8x reduced mortality; FOXO4-DRI's key evidence is a single 2017 Cell paper in mice with no human trials.
- Dosing: Epithalon is dosed at 5-10 mg daily for 10-20 days, repeated every 4-6 months; FOXO4-DRI has only mouse protocols (5 mg/kg every other day for 3 doses) with no validated human equivalent.
- Side effects: Epithalon side effects are generally mild (injection site discomfort, rare flu-like symptoms, drowsiness); FOXO4-DRI has no human safety data and theoretical risk of off-target apoptosis.
- Legal status: Both are research-only compounds with no FDA approval; epithalamin (the natural extract) is approved in Russia as a pharmaceutical.
- Structure: Epithalon is a simple tetrapeptide (Ala-Glu-Asp-Gly, MW 390); FOXO4-DRI is a large D-amino acid peptide (MW 4827) with protease-resistant retro-inverso configuration.
The verdict
Epithalon and FOXO4-DRI target complementary hallmarks of aging — telomere attrition and cellular senescence, respectively. Epithalon has a substantially longer research history and some human observational data, though most comes from Russian studies with limited Western peer review. FOXO4-DRI has a more compelling mechanistic narrative (the 2017 Cell paper) but far less total evidence and no human safety data. Both remain research-stage compounds, and their different mechanisms mean they are not directly interchangeable.
Frequently asked questions
Because they target different hallmarks of aging (telomere maintenance vs senescent cell clearance), some longevity researchers combine them. No studies have evaluated this combination. The rationale is that epithalon preserves cellular replicative capacity while FOXO4-DRI removes cells that have already become dysfunctional.
Epithalon has a larger body of research spanning 35+ years, including over 100 publications and a 15-year human observational study. FOXO4-DRI evidence rests primarily on the landmark 2017 Cell paper by Baar et al. and subsequent preclinical studies. However, most epithalon human data comes from Russian studies with limited Western peer review.
No human safety data exists for FOXO4-DRI. No human clinical trials have been completed, no IND has been filed, and human pharmacokinetic data is entirely unknown. Animal studies suggest potential off-target apoptosis in non-senescent cells at high doses. It is a research chemical only.
Epithalon works preventively by activating telomerase to maintain telomere length, theoretically slowing the rate at which cells reach senescence. FOXO4-DRI works remedially by clearing cells that have already become senescent. In the hallmarks of aging framework, they address telomere attrition and cellular senescence, which are related but distinct processes.
FOXO4-DRI is substantially more expensive per treatment cycle due to its larger molecular weight (4827 vs 390 Da), more complex D-amino acid retro-inverso synthesis, and limited supplier base. Epithalon's simple tetrapeptide structure makes it relatively inexpensive to synthesize by comparison.